Transtech Pharma, Inc.

Smithkline Beecham Corporation

Vtv Therapeutics LLC

Glaxo Wellcome Inc.

High Point Pharmaceuticals, LLC

Stephen Thomas Davis

Adnan M M Mjalli

Dharma Rao Polisetti

Mustafa Guzel

Thomas Scott Yokum

Christopher Behme

Kalpathy Chidambareswaran Santhosh

Robert Carl Andrews

James Marvin Veal

Michael Luzzio

Philip Anthony Harris

Scott Howard Dickerson

Muralidhar Bondlela

Lee Frederick Kuyper

Robert Neil Hunter, Iii

Duncan Herrick Walker

Karen Elizabeth Lackey

Daniel Peter Christen

Ramesh Gopalaswamy

Devi Reddy Gohimukkula

Ravindra Reddy Yarragunta

Jennifer L R Freeman

Govindan Subramanian

Jeff Jiqun Zhu

James C Quada, Jr

Stephen V Frye

Santhosh Kalpathy

Bapu Reddy Gaddam

Maria Carmen Valcarce Lopez

Murty N Arimilli

Xiaochuan Guo

Brian S Grella

Mohan Rao

Tan Ren

Adnan Mm Mjalli

Suvi Simila

James Quada

Jr James C Quada

Jennifer LR Freeman

Adnan MM Mjalli

Bradley Alan Clark

Daniel P Christen

The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.

Substituted azoanthracene derivatives and intermediates for preparation thereof

The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R, R, R, Rand Rare as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.

Oxadiazoanthracene compounds for the treatment of diabetes

The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

The present invention provides methods of synthesizing oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R, R, R, Rand Rare as herein described, and methods of synthesizing precursors to these oxadiazoanthracene derivatives.

The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R, R, R, Rand Rare as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.

Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors

The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R, R, R, Rand Rare as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).

Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.

Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use

Compounds of formula (I): wherein X is N, CH, CCF, or C(Caliphatic); Ris sulfonic acid, Caliphatic-sulfonyl, sulfonyl-Caliphatic, Caliphatic-sulfonyl-Caliphatic, Caliphatic-amino, R-sulfonyl, Rsulfonyl-Caliphatic, R-aminosulfonyl, R-aminosulfonyl-Caliphatic, R-sulfonylamino, R-sulfonylamino-Caliphatic, aminosulfonylamino, di-Caliphatic amino, di-Caliphatic aminocarbonyl, di-Caliphatic aminosulfonyl, di-Caliphatic amino, di-Caliphatic aminocarbonyl, di-Caliphatic aminosulfonyl-Caliphatic, (R)-Arylamino, (R)-Arylsulfonyl, (R)-Aryl-aminosulfonyl, (R)-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, Ris hydrogen; and further wherein Rand Rare optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects

A composition and method for preventing/reducing the severity of epithelial cytoxicity side effects such as alopecia, plantar-palmar syndrome, mucositis) induced by chemoptherapy and/or radiation therapy in a patient receiving such therapy wherein a cyclin-dependent kinase II inhibitor is contemporaneously administered to the patient.

Method for reducing the severity of side effects of chemotherapy and/or radiation therapy

Growing community of inventors

Durham, NC, United States of America

Stephen Thomas Davis